Clinical trials: Autoimmune Liver Disease
Type 1 Diabetes, Pancreatectomy; Hyperglycemia
Collection of Human Liver Biopsy and Whole Blood Samples From T1DM, TP or PP Patients for Potential Use for Insulin Producing Cells in Future Clinical Studies
In this study, liver samples will be collected, processed and stored in a specialized, clinical grade, cell bank for potential future clinical use.
- Trial name
- NCT04038931
- Testing
- Liver biopsy collection
- Volunteers
- 20 people
- Sponsor
- Orgenesis Ltd.
Autoimmune Hepatitis
LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs.
- Trial name
- NCT00608894
- Testing
- LCP-Tacro (tacrolimus), Azathioprine
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Veloxis Pharmaceuticals
Autoimmune Hepatitis
Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)
This is a Phase 2 study. All patients will receive prednisolone and AZA as standard of care (SOC) during the study. At the end of the study, all data collected will be analyzed the efficacy and safety of JKB-122 on SOC reduction…
- Trial name
- NCT04371718
- Testing
- JKB-122
- Volunteers
- 120 people
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
Autoimmune Diseases, Inflammation
Prospective Study of White Blood Cells
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
- Conditions
- Autoimmune Diseases, Inflammation, Rejection; Transplant, Liver
- Trial name
- NCT04838171
- Testing
- White blood cell and blood collection
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Quell Therapeutics Limited
Multiple Sclerosis, Relapsing-Remitting
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate…
- Trial name
- ORION (NCT05605782)
- Where
- United States
- Volunteers
- 9,000 people
- Sponsor
- Bristol-Myers Squibb
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment
The primary objective of this study will be to evaluate the pharmacokinetic properties of avacopan and its metabolite CCX168-M1 after a single oral dose of 30 mg avacopan in participants with mild or moderate hepatic impairment…
- Trial name
- NCT06004934
- Testing
- Avacopan
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amgen
Autoimmune Hepatitis
A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis
Subjects with stable autoimmune hepatitis disease currently being administered corticosteroids with or without azathioprine (AZA) treatment will be be treated with Cannabidiol instead of standard of care treatment with…
- Trial name
- NCT04129489
- Testing
- Cannabidiol
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Stero Biotechs Ltd.
Autoimmune Hepatitis
AIH Risk Stratification With Multiparametric MRI
The primary aim of this study is to investigate whether the baseline cT1 can predict those whose condition relapses following treatment withdrawal.
- Trial name
- NCT04339621
- Testing
- LiverMultiscan
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Perspectum
Autoimmune Hepatitis
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
This study will evaluate the efficacy and safety of HR19042 capsules for the treatment of autoimmune hepatitis. It will also explore the optimal frequency and dosage of HR19042 capsules administration for the treatment.
- Trial name
- NCT05476900
- Testing
- HR19042 Capsules
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 1 Diabetes Mellitus
Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus
This is a multicenter, randomized, partial-blinded, five-arm, placebo-controlled study of human plasma-derived alpha1-proteinase inhibitor (alpha1-PI) in children (ages 6-11 years old) and teens/adults (ages 12-35 years old) with…
- Trial name
- NCT02093221
- Testing
- 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI
- Where
- 36 sites in United States
- Volunteers
- 76 people
- Sponsor
- Grifols Therapeutics LLC
Autoimmune Hepatitis
Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
This is a Phase 2, pilot study in which JKB-122 is given once daily for 24 weeks in subjects with autoimmune hepatitis (AIH) who have liver enzymes that are 1.25 to 10 times the upper limit of normal (ULN) and who have had a…
- Trial name
- NCT02556372
- Testing
- JKB-122
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
Autoimmune Hepatitis
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
VAY736 dose testing; VAY736 efficacy and safety testing.
- Trial name
- AMBER (NCT03217422)
- Testing
- VAY736
- Where
- 28 sites in United States, Argentina and 8 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals